Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study

NCT ID: NCT06851845

Last Updated: 2025-02-28

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 100 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2026-02-01
• Study Completion Date: 2028-02-01

Brief Summary

The study is planned to study specificity of the clinical course and treatment outcomes of C3 glomerulopathy (C3G) and Immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged under 18 years and 18 years and older in the Russian population in 2025-2028. The primary objective of the study is to estimate the frequency of complete or partial remission 12 months after morphological verification of the diagnosis. Assessment of demographic, clinical and laboratory, morphological characteristics at diagnosis and their relationship with the disease outcomes, primarily the disease progression and development of chronic renal failure, will allow assessing the efficacy of treatment used in real clinical practice, disease prognosis and factors associated with unfavourable outcomes.

Conditions

Kidney Diseases

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

C3 glomerulopathy

Diagnosis of primary C3G confirmed by the results of morphological and clinical studies.

No intervention

Intervention Type: OTHER

Patients will receive medical care in accordance with the routine practice of disease treatment

Immune-complex membranoproliferative glomerulonephritis

Diagnosis of primary IC-MPGN confirmed by the results of morphological and clinical studies.

No intervention

Intervention Type: OTHER

Patients will receive medical care in accordance with the routine practice of disease treatment

Interventions

No intervention

Patients will receive medical care in accordance with the routine practice of disease treatment

Intervention Type: OTHER

Other Intervention Names

Treatment includes the following options: ACEi/ARB alone; ACEi/ARB + corticosteroids; ACEi/ARB + MMF; ACEi/ARB + SGLT2i; ACEi/ARB + MMF + corticosteroids; ACEi/ARB + cyclophosphamide; Corticosteroids alone; MMF alone; Cyclophosphamide alone; Corticosteroids + MMF; Rituximab; Anticomplement therapy; Other immunosuppressants

Eligibility Criteria

Inclusion Criteria

1. Willing to sign informed consent form. If the patient is under 18 years of age, the parent or legally acceptable representative of the child/adolescent who can participate in this study also signs the consent form.

2. Diagnosis of primary C3G or IC-MPGN confirmed by the results of morphological and clinical studies.

3. The results of serum creatinine level, proteinuria determination obtained not earlier than 4 weeks before the kidney biopsy

4. Index date (kidney biopsy) not earlier than March 2024 and not later than 11 months before signing the ICF

5. The estimated baseline GFR (using the CKD-EPI formula for persons aged over 18 years and the modified Schwarz formula for children) or the measured GFR is ≥30 mL/min per 1.73 m2.

Exclusion Criteria

1. Patients participating in a clinical trial with the investigational product.

2. Patients with monoclonal gammopathies (myeloma, B-cell lymphoma/lymphocytic leukemia, lymphoplasmacytoma)

3. Patients with systemic autoimmune diseases and vasculitis (systemic lupus erythematosus, systemic sclerosis, dermatomyositis, mixed connective tissue disease, Sjogren syndrome, Henoch-Schönlein purpura, ANCA vasculitis, cryoglobulinemia)

4. Patients with current or recent infections (viral hepatitis B, viral hepatitis C, infective endocarditis or sepsis, infected ventriculoatrial shunts, abscesses, meningococcal and other bacterial infections, protozoan infections)

5. Patients with any clinically significant acute disease within 30 days prior to kidney biopsy

6. Clinically significant concomitant kidney disease

7. Treatment with pegcetacoplan

• Minimum Eligible Age: 0 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Novartis Pharmaceuticals

Role: CONTACT

novartis.email@novartis.com

+41613241111

Novartis Pharmaceuticals

Role: CONTACT

Other Identifiers

CLNP023B1RU01

Identifier Type: -

Identifier Source: org_study_id